Opinion|Videos|January 1, 2025
Patient Case No. 1
Key Takeaways
- Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic.
- It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment.
Panelists discuss how evaluating uncontrolled hypertension in patients with early kidney dysfunction requires a careful investigation of underlying causes, including medication adherence, lifestyle factors, and potential secondary hypertension.
Advertisement
Episodes in this series
- Patient No. 1 has uncontrolled hypertension despite the use of 4 antihypertensive drugs. They have a slightly abnormal estimated glomerular filtration rate suggestive of early kidney involvement. Their creatinine level is elevated, indicating impaired renal function.
- How would you approach the cause of uncontrolled blood pressure in this patient?
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Advertisement
Advertisement
Trending on HCPLive
1
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5